These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7962378)

  • 1. Pulsatile subcutaneous versus bolus intramuscular gonadotrophin administration after pituitary suppression with a long-acting gonadotrophin-releasing hormone analogue: a controlled prospective study.
    De Geyter C; De Geyter M; Simoni M; Castro E; Bals-Pratsch M; Nieschlag E; Schneider HP
    Hum Reprod; 1994 Jun; 9(6):1070-6. PubMed ID: 7962378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian stimulation for in-vitro fertilization combining administration of gonadotrophins and blockade of the pituitary with D-Trp6-LHRH microcapsules: pilot studies with two protocols.
    Zorn JR; Barata M; Brami C; Epelboin S; Nathan C; Papageorgiou G; Quantin P; Rolet F; Savale M; Boyer P
    Hum Reprod; 1988 Feb; 3(2):235-9. PubMed ID: 2965712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins.
    Wildt L; Diedrich K; van der Ven H; al Hasani S; Hübner H; Klasen R
    Hum Reprod; 1986 Jan; 1(1):15-9. PubMed ID: 2971082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study.
    Dal Prato L; Borini A; Trevisi MR; Bonu MA; Sereni E; Flamigni C
    Hum Reprod; 2001 Jul; 16(7):1409-14. PubMed ID: 11425821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
    Chen X; Feng SX; Guo PP; He YX; Liu YD; Ye DS; Chen SL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):215-220. PubMed ID: 27072965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Nugent D; Vandekerckhove P; Hughes E; Arnot M; Lilford R
    Cochrane Database Syst Rev; 2000; (4):CD000410. PubMed ID: 11034687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization.
    Cedrin-Durnerin I; Bidart JM; Robert P; Wolf JP; Uzan M; Hugues JN
    Hum Reprod; 2000 May; 15(5):1009-14. PubMed ID: 10783343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF.
    Janssens RM; Vermeiden JP; Lambalk CB; Schats R; Schoemaker J
    Hum Reprod; 1998 Sep; 13(9):2386-91. PubMed ID: 9806254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An artificially induced follicle stimulating hormone surge at the time of human chorionic gonadotrophin administration in controlled ovarian stimulation cycles has no effect on cumulus expansion, fertilization rate, embryo quality and implantation rate.
    Vermeiden JP; Roseboom TJ; Goverde AJ; Suchartwatnachai C; Schoute E; Braat DD; Schats R
    Hum Reprod; 1997 Jul; 12(7):1399-402. PubMed ID: 9262265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined GnRH-agonist/gonadotrophin stimulation for in-vitro fertilization.
    Schmutzler RK; Reichert C; Diedrich K; Wildt L; Diedrich C; Al-Hasani S; van der Ven H; Krebs D
    Hum Reprod; 1988 Oct; 3 Suppl 2():29-33. PubMed ID: 2976414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF.
    Yim SF; Lok IH; Cheung LP; Briton-Jones CM; Chiu TT; Haines CJ
    Hum Reprod; 2001 Mar; 16(3):492-4. PubMed ID: 11228217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
    Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
    Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.